Literature DB >> 33653753

Temporal trends in heart failure medication prescription in a population-based cohort study.

Alicia Uijl1,2,3,4, Ilonca Vaartjes5, S Denaxas3,4,6,7, Harry Hemingway3,4,7, Anoop Shah3,4, J Cleland8,9, Diederick Grobbee5, Arno Hoes5, Folkert W Asselbergs3,4,10,11, Stefan Koudstaal3,4,10.   

Abstract

OBJECTIVE: We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR).
METHODS: From primary and secondary care EHR, we identified 85 732 patients with a HF diagnosis between 2002 and 2015. Almost 50% of patients with HF were women and the median age was 79.1 (IQR 70.2-85.7) years, with age at diagnosis increasing over time.
RESULTS: We found several trends in pharmacological HF management, including increased beta blocker prescriptions over time (29% in 2002-2005 and 54% in 2013-2015), which was not observed for mineralocorticoid receptor-antagonists (MR-antagonists) (18% in 2002-2005 and 18% in 2013-2015); higher prescription rates of loop diuretics in women and elderly patients together with lower prescription rates of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, beta blockers or MR-antagonists in these patients; little change in medication prescription rates occurred after 6 months of HF diagnosis and, finally, patients hospitalised for HF who had no recorded follow-up in primary care had considerably lower prescription rates compared with patients with a HF diagnosis in primary care with or without HF hospitalisation.
CONCLUSION: In the general population, the use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up. For most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  cardiac epidemiology; heart failure; public health

Mesh:

Substances:

Year:  2021        PMID: 33653753      PMCID: PMC7929882          DOI: 10.1136/bmjopen-2020-043290

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  27 in total

1.  Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women.

Authors:  Pooja Dewan; Rasmus Rørth; Pardeep S Jhund; Li Shen; Valeria Raparelli; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Ulrik M Mogensen; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2019-01-08       Impact factor: 24.094

2.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

3.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

5.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

6.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

7.  Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy.

Authors:  F Peters-Klimm; T Müller-Tasch; D Schellberg; A Remppis; A Barth; N Holzapfel; J Jünger; W Herzog; J Szecsenyi
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

8.  Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.

Authors:  Stephen J Greene; Gregg C Fonarow; Adam D DeVore; Puza P Sharma; Muthiah Vaduganathan; Nancy M Albert; Carol I Duffy; C Larry Hill; Kevin McCague; J Herbert Patterson; John A Spertus; Laine Thomas; Fredonia B Williams; Adrian F Hernandez; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2019-03-04       Impact factor: 24.094

9.  Treatment of chronic heart failure in Germany: a retrospective database study.

Authors:  Stefan Störk; Renate Handrock; Josephine Jacob; Jochen Walker; Frederico Calado; Raquel Lahoz; Stephan Hupfer; Sven Klebs
Journal:  Clin Res Cardiol       Date:  2017-07-26       Impact factor: 5.460

10.  Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people.

Authors:  Stefan Koudstaal; Mar Pujades-Rodriguez; Spiros Denaxas; Johannes M I H Gho; Anoop D Shah; Ning Yu; Riyaz S Patel; Chris P Gale; Arno W Hoes; John G Cleland; Folkert W Asselbergs; Harry Hemingway
Journal:  Eur J Heart Fail       Date:  2016-12-23       Impact factor: 15.534

View more
  1 in total

1.  Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study.

Authors:  Julie Rouette; Emily G McDonald; Tibor Schuster; James M Brophy; Laurent Azoulay
Journal:  BMJ Open       Date:  2022-06-10       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.